Results 11 to 20 of about 75,218 (96)

Engineered probiotics Clostridium butyricum‐pMTL007‐GLP‐1 improves blood pressure via producing GLP‐1 and modulating gut microbiota in spontaneous hypertension rat models

Microbial Biotechnology, 2023
Hypertension is a significant risk factor of cardiovascular diseases (CVDs) with high prevalence worldwide, the current treatment has multiple adverse effects and requires continuous administration.
Xin‐liang Wang, Wen‐jie Chen, Rui Jin, Xuan Xu, Jing Wei, Hong Huang, Yan‐hua Tang, Chang‐wei Zou, Ting‐tao Chen   +8 more
doaj   +1 more source

The Anthocyanin Delphinidin 3-Rutinoside Stimulates Glucagon-Like Peptide-1 Secretion in Murine GLUTag Cell Line via the Ca2+/Calmodulin-Dependent Kinase II Pathway. [PDF]

PLoS ONE, 2015
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from enteroendocrine L-cells. Although several nutrients induce GLP-1 secretion, there is little evidence to suggest that non-nutritive compounds directly increase GLP-1 secretion.
Masaki Kato, Tsubasa Tani, Norihiko Terahara, Takanori Tsuda   +3 more
doaj   +1 more source

β Cell GLP-1R Signaling Alters α Cell Proglucagon Processing after Vertical Sleeve Gastrectomy in Mice

Cell Reports, 2018
Summary: Bariatric surgery, such as vertical sleeve gastrectomy (VSG), causes high rates of type 2 diabetes remission and remarkable increases in postprandial glucagon-like peptide-1 (GLP-1) secretion.
Darline Garibay, Jon Lou, Seon A. Lee, Karolina E. Zaborska, Margot H. Weissman, Erica Sloma, Leanne Donahue, Andrew D. Miller, Andrew C. White, M. Dodson Michael, Kyle W. Sloop, Bethany P. Cummings   +11 more
doaj   +1 more source

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors

Physiological Reports, 2017
Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone increasing postprandial insulin release. GLP‐1 also induces diuresis and natriuresis in humans and rodents. The GLP‐1 receptor is extensively expressed in the renal vascular tree in normotensive rats
Jonas Ronn, Elisa P. Jensen, Nicolai J. Wewer Albrechtsen, Jens Juul Holst, Charlotte M. Sorensen   +4 more
doaj   +1 more source

GLP‐1 Is a Coronary Artery Vasodilator in Humans

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background The mechanism underlying the beneficial cardiovascular effects of the incretin GLP‐1 (glucagon‐like peptide 1) and its analogues in humans is elusive.
Sophie J. Clarke, Joel P. Giblett, Lucy L. Yang, Annette Hubsch, Tian Zhao, Muhammad Aetesam‐ur‐Rahman, Nick E. J. West, Michael O'Sullivan, Nichola Figg, Martin Bennett, Nicolai J. Wewer Albrechtsen, Carolyn F. Deacon, Joseph Cheriyan, Stephen P. Hoole   +13 more
doaj   +1 more source

Discrepancy between the Actions of Glucagon-like Peptide-1 Receptor Ligands in the Protection of the Heart against Ischemia Reperfusion Injury

Pharmaceuticals, 2022
Tirzepatide is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and a promising therapy for type 2 diabetes mellitus (T2DM). GLP-1 is an incretin hormone with therapeutic potential beyond type
Ali Ismaeil, Fawzi Babiker, Suleiman Al-Sabah   +2 more
doaj   +1 more source

Adverse effects of GLP – 1 Receptor Agonists

Journal of Education, Health and Sport
Introduction and purpose Glucagon-like peptide-1 receptor agonists (GLP – 1 RAs) are indicated in type 2 diabetes (T2D) and obesity because of their high efficacy in controlling blood glucose levels and inducing weight loss.
Anna Kasprzak, Monika Kułaga, Monika Grzybek, Diana Mazur-Lesińska, Barbara Szostak, Sylwia Wielgosz-Biała, Krzysztof Tyszkiewicz, Borys Łozowski, Małgorzata Kasprzak, Barbara Wilczyńska   +9 more
doaj   +1 more source

Recent advances in understanding the role of glucagon-like peptide 1 [version 1; peer review: 2 approved]

F1000Research, 2020
The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the incretin effect during the postprandial period and the subsequent observation that GLP-1 bioactivity is retained in type 2 diabetes (T2D) led to new therapeutic ...
Josh Reed, Stephen Bain, Venkateswarlu Kanamarlapudi   +2 more
doaj   +1 more source

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review

Hepatic Medicine: Evidence and Research, 2020
Getnet Teshome,1 Sintayehu Ambachew,2 Alebachew Fasil,2 Molla Abebe2 1University of Gondar Comprehensive Specialized Hospital, University of Gondar, Gondar, Amhara, Ethiopia; 2Department of Clinical Chemistry, University of Gondar, Gondar, Amhara ...
Teshome G, Ambachew S, Fasil A, Abebe M
doaj  

Chronic exposure to GLP-1 increases GLP-1 synthesis and release in a pancreatic alpha cell line (α-TC1): evidence of a direct effect of GLP-1 on pancreatic alpha cells.

PLoS ONE, 2014
Aims/hypothesisIncretin therapies, which are used to treat diabetic patients, cause a chronic supra-physiological increase in GLP-1 circulating levels.
Salvatore Piro, Loriana G Mascali, Francesca Urbano, Agnese Filippello, Roberta Malaguarnera, Salvatore Calanna, Agata M Rabuazzo, Francesco Purrello   +7 more
doaj   +1 more source